SINGAPORE · MEDICAL DEVICES

Changing Your Singapore Medical Device Registrant: How to Transfer Without Breaking Supply

When a manufacturer decides to change its Singapore distributor, the first discussions usually cover stock, customers and pricing. Only later does it emerge that the products are still registered under the outgoing partner’s name, and that the new partner cannot take over the registration on the strength of a commercial authorisation alone. What actually needs to be managed is not a certificate, but the continuity of registrant identity, submitted dossiers and post-market responsibilities.

Devices already registered in Singapore can change registrant through HSA’s Change of Registrant procedure, but appointing a new company does not mean the transfer has taken effect. For manufacturers, the prudent approach is to confirm the applicable route first, then schedule the regulatory application and the commercial switch as separate tracks; the two tracks meet on the approval date, rather than using the contract termination date as a substitute for the regulatory effective date.

Why does changing distributor not always mean changing registrant?

The registrant is the entity that applies for and holds the product registration; import and wholesale are a separate layer of business activity. HSA manages product registration and dealer’s licensing separately. If the outgoing distributor also holds the product registration, a change of channel may trigger a change of registrant; if the registration is held by a separate, independent entity and only the sales channel is changing, the first things to check are the import and wholesale licences, the authorisation relationships and the quality agreement, rather than going straight to a transfer of registration. (Source: HSA Medical Devices Regulatory Overview, 5 Jun 2026, “Scope of regulation”, “Dealer’s licensing”)

The last scenario is the one most easily underestimated. HSA classifies product changes separately; a change of intended use, for example, is not something a general CN can handle. Combining “change the holder” and “change the product” into one project does not automatically merge the two sets of requirements. (Source: HSA Change Notification page, 21 Oct 2026, “When a Change Notification is required”)

What is HSA actually confirming with the three-party documents?

The application is submitted by the new registrant via SHARE, with a separate application for each product owner involved. The core documents are the product owner’s new authorisation letter and request letter, together with a declaration from the outgoing registrant, which must be signed by a director or senior management. The devices must already be listed on the SMDR, and any related pending applications should be completed or withdrawn first. (Source: HSA GN-24 R2, Jul 2025, §2; Annex 1–2)

From a project-management perspective, these documents respectively confirm “who appoints”, “who takes over” and “who hands over”, and none can substitute for another. Before signing anything, prepare a master registration list that maps SMDR listing names, registration numbers, product owners, model ranges and pending matters against each other, then sign the documents on that basis. Otherwise, missing one listing under the same brand, or naming the manufacturing site as the product owner by mistake, can leave the commercial agreement and the regulatory application pointing at different parties.

The appointment date of the new registrant stated in the request letter should precede the submission, but the actual change of registrant takes effect only on HSA approval. Companies can arrange handover work in advance, but should not tell customers that the registration has been transferred simply because the application has been submitted.

How should “at least two months” and “40 working days” be used in scheduling?

GN-24 states that the listing must be “valid for at least the next two months before the next retention due date”. The requirement is that the listing should still have at least two months of validity ahead of it before the next annual retention due date; it does not mean “keep it for two more months after expiry”, and it is not an additional grace period. (Source: GN-24 R2, §2; §3)

The HSA fees page currently lists the Change of Registrant application fee as S$880, with a target processing time of 40 working days; the time during which the clock is stopped while the applicant responds to requests for additional information is excluded. The page is marked as updated on 26 March 2026 and should still be re-checked at the time of submission. In MediPass’s experience, a complete application is usually approved within about two weeks; the 40 working days is the official upper target, not the typical turnaround. (Source: HSA Medical Device Fees and Turnaround Times, “Change of registrant”)

The management implication is that “two months” cannot be treated as a safe total project duration. Signatures, clearing pending applications, document verification and responses to queries all take time. If a product is close to its annual retention date, agree first on who will complete that retention, and how payment and listing status will be confirmed, before scheduling the transfer. Annual retention fees already paid by the outgoing registrant are not refunded, and the new registrant bears the fee from the first annual retention after the transfer takes effect; the application fee for a submitted transfer is likewise not refunded on withdrawal or rejection (GN-24, §3–4). The contract should distinguish these government fees from service fees and stock settlement, so that payment disputes do not affect listing maintenance.

If the outgoing registrant refuses to sign, is a transfer impossible?

The accurate statement is that, without the outgoing registrant’s declaration, the documentary requirements of the standard procedure have not been met. GN-24 does not publish any general “alternative document for refusal” mechanism, while reserving HSA’s discretion over each application; it is therefore inappropriate either to promise that the outgoing registrant can be bypassed, or to assert that no individual case has any room for resolution. (Source: GN-24 R2, §1.2; §2)

Start by identifying the reason for the refusal. If it is a fee or contract dispute, the commercial and legal teams need to deal with the handover obligations; if the company has ceased operations, the contact person cannot be reached or the entity has changed, gather objective evidence and ask HSA what handling is acceptable for that case. A manufacturer revoking the old authorisation does not by itself prove that the registration in the system has been transferred. Re-registration can be assessed as an option, but its feasibility, timing and the handling of the existing listing should be confirmed first; it is not a guaranteed faster alternative.

After approval, which records and supply arrangements must not be overlooked?

The 2025 edition, GN-24 R2, adds an important detail: after a successful transfer, the new registrant can access the information and dossier submitted by the outgoing registrant for the relevant listings, and the outgoing registrant’s access to those listings ends. Dossiers submitted in the system are not the same as supply and complaint records. The latter may be retained by the outgoing registrant in accordance with the law, or handed over to the new registrant; if they are retained, they must still be provided to the new registrant or HSA when a field safety corrective action (FSCA) occurs or the authority requests them. (Source: GN-24 R2, §2–3; Annex 2)

The handover agreement should therefore state where records are kept, who is responsible, how they can be retrieved and the response time in an emergency, rather than simply “both parties will cooperate”. The following is a hypothetical scenario, not a real client case: three weeks after the transfer, the product owner asks to trace a batch of devices from the previous year. If the new company has the dossier but does not know which hospitals that batch was sold to, the registration transfer may be approved while recall execution still stalls. As part of handover acceptance, it is best to pick one batch number and test whether it can be traced from shipping records to the customer, and then linked back to complaint and handling records.

Supply also needs to be verified separately. HSA states that import of registered devices must normally be carried out by a licensed dealer authorised by the registrant; import without the registrant’s authorisation has its own case-by-case approval route and is not an automatic transitional arrangement under an ordinary transfer. (Source: HSA page on consignment import of registered devices, 26 Mar 2026, “Conditions”)

This means that, before and after approval, orders in transit, the entity holding the stock, import authorisation, complaint intake and customer notification should each be checked item by item. Do not assume that any company can continue to import or sell simply because the registration now carries a different name.

What is the value of an independent registrant, and what can it not replace?

Separating registration management from the sales channel has commercial value: it reduces the likelihood that every change of distributor affects the registrant entity, and gives dossiers, renewals and post-market coordination a more stable interface. This is a governance arrangement, not a regulatory exemption: an independent registrant must still fulfil its obligations, the manufacturer must still provide technical and safety support, and the distributor must still hold the relevant licences. When choosing a service provider, review the legal entity that actually bears responsibility, dossier access rights, exit obligations and emergency coordination capability, rather than comparing annual holding fees alone.

A short checklist before starting: confirm all listings and annual retention due dates; clear pending applications; secure the three-party signatures; test that historical records are usable; confirm in writing who is responsible for supply before and after the approval date.